Saroglitazar: Dual PPAR Agonist for Lipids & NASH
Saroglitazar is an innovative pharmaceutical agent classified as a dual PPAR agonist ($\alpha$ and $\gamma$). This unique mechanism allows it to simultaneously improve lipid metabolism (lowering triglycerides) and enhance insulin sensitivity.
The drug is designed to treat complex metabolic disorders, including diabetic dyslipidemia and non-alcoholic steatohepatitis (NASH). On Unifarm, you can find a list of medications containing this active ingredient.
Indications
- Diabetic Dyslipidemia: Treatment of hypertriglyceridemia in patients with Type 2 Diabetes Mellitus not controlled by statin therapy alone.
- Hypertriglyceridemia: High blood triglyceride levels unrelated to diabetes.
- Non-Alcoholic Steatohepatitis (NASH): To reduce liver inflammation and fibrosis.
- Non-Alcoholic Fatty Liver Disease (NAFLD): In patients with metabolic comorbidities.
Dosage and administration
Saroglitazar medications are taken orally, typically once daily, with or without food.
Standard Regimen:
- The recommended dose is 4 mg once daily.
- The tablet should be swallowed whole with water.
- No dose adjustment is required for elderly patients.
The duration of treatment and the need for combination with statins are determined by the physician.
- Hypersensitivity to the drug components.
- Severe hepatic impairment or decompensated liver disease (despite indication for NASH, severe forms require caution).
- Severe renal impairment.
- Pregnancy and breastfeeding.
- Age under 18 years.
Saroglitazar generally does not cause weight gain or edema typical of other glitazone-class drugs. Possible reactions include:
- Gastrointestinal: Gastritis, abdominal discomfort, dyspepsia, flatulence.
- General: Asthenia (weakness), pyrexia (fever).
- Respiratory: Nasopharyngitis.
- Musculoskeletal: Myalgia (rarely).
